PLYMOUTH MEETING, Pa. - Harmony Biosciences Holdings , Inc. (NASDAQ:HRMY), a pharmaceutical company focused on rare neurological diseases, has initiated an underwritten public offering of 8,000,000 shares of its common stock. The offering is being made by two of its shareholders, Marshman Fund Trust II and Valor IV Pharma Holdings, LLC. These shareholders are also offering the underwriters a 30-day option to purchase up to an additional 1,200,000 shares. Harmony Biosciences will not be selling any shares nor will it receive proceeds from this offering.
J.P. Morgan is the sole book-running manager for the transaction. The shares are being offered pursuant to an existing shelf registration statement with the Securities and Exchange Commission (SEC), and the sale will be conducted through a prospectus supplement and accompanying base prospectus available from J.P. Morgan or the SEC's website.
This announcement comes as Harmony Biosciences continues its mission to develop therapies for patients with unmet medical needs in the area of rare neurological conditions. The company, established in 2017 and based in Plymouth Meeting, Pennsylvania, emphasizes a combination of novel science and a vision to support overlooked patient communities.
The press release for this event includes forward-looking statements, which are based on current expectations and projections about future events. These statements are subject to risks and uncertainties that could cause actual outcomes to differ materially from those anticipated. Harmony Biosciences advises caution in placing reliance on these forward-looking statements, which are valid only as of the date of the press release.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities, nor will there be any sale of these securities in any jurisdiction where such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that jurisdiction.
The information in this article is based on a press release statement from Harmony Biosciences.
In other recent news, Harmony Biosciences reported a 29% rise in Q2 net sales for its product WAKIX, reaching $172.8 million. The company maintains a solid financial position with $434.1 million in cash, cash equivalents, and investments. Harmony Biosciences is on track to meet its 2024 net revenue guidance of $700 million to $720 million. Mizuho reiterated its Outperform rating on Harmony Biosciences stock, anticipating a breakout year for the company in 2025. Goldman Sachs, however, reaffirmed its Sell rating, citing the need for further clinical validation of the company's pipeline. Meanwhile, Raymond James resumed coverage with an Outperform rating, highlighting potential growth opportunities following the dismissal of the Citizen's Petition and the expansion of the drug Wakix's label for pediatric use. Piper Sandler maintained its Overweight rating, emphasizing the company's growth strategies and pipeline developments. These are all recent developments in Harmony Biosciences' journey.
InvestingPro Insights
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has been demonstrating strong financial performance, which may be of interest to investors considering the recent public offering announcement. According to InvestingPro data, the company's revenue growth stands at an impressive 31.52% over the last twelve months as of Q2 2024, with a robust gross profit margin of 79.41%. This solid growth trajectory aligns with the company's focus on developing therapies for rare neurological conditions.
InvestingPro Tips highlight that Harmony Biosciences has been aggressively buying back shares, which could be seen as a sign of confidence from management in the company's future prospects. Additionally, the company operates with a moderate level of debt, suggesting a balanced approach to financial management.
The stock's performance has been noteworthy, with a one-year price total return of 86.2% as of the latest data. This strong return, coupled with the fact that the stock is trading near its 52-week high, may explain the timing of the public offering by the selling shareholders.
For investors seeking more comprehensive analysis, InvestingPro offers 10 additional tips for Harmony Biosciences, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.